Abstract
We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-Arrhythmia Agents / therapeutic use*
-
Diagnosis, Differential
-
Electrocardiography
-
Female
-
Genetic Predisposition to Disease
-
Humans
-
Male
-
Middle Aged
-
Pedigree
-
Sotalol / therapeutic use*
-
Syndrome
-
Ventricular Fibrillation / diagnosis*
-
Ventricular Fibrillation / drug therapy*
-
Ventricular Fibrillation / genetics
-
Ventricular Fibrillation / physiopathology
Substances
-
Anti-Arrhythmia Agents
-
Sotalol